<DOC>
	<DOCNO>NCT01089725</DOCNO>
	<brief_summary>This efficacy safety study 3 dos ( 2.5 mg , 5 mg 10mg ) tanezumab administer subcutaneously versus placebo . This study also compare subcutaneous ( SC ) administration 10 mg tanezumab ) intravenous ( IV ) administration 10 mg tanezumab . Each person receive IV infusion SC infusion . The study last 16 week wish enter 64-week extension study 24 week .</brief_summary>
	<brief_title>Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study</brief_title>
	<detailed_description>This study terminate 08 Nov 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Diagnosis osteoarthritis ( OA ) knee accord American College Rheumatology ( ACR ) criteria Kellgren Lawrence score great equal 2 18 year age great Two method birth control one must barrier childbearing potential Willing discontinue pain medication except permit per protocol Pregnancy wish pregnant course study , lactate woman Body Mass Index ( BMI ) great 39 Clinically significant cardiac , neurological , psychiatric condition condition exclude protocol . Previous exposure Nerve Growth Factor ( NGF ) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>parallel group</keyword>
	<keyword>double-blind</keyword>
	<keyword>multicenter</keyword>
	<keyword>injection</keyword>
	<keyword>infusion</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>bridging</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>intravenous</keyword>
	<keyword>tanezumab</keyword>
</DOC>